Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis

BACKGROUND: Patients with non‐alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, are at higher risk of cardiovascular disease (CVD) and associated mortality. Therefore, it is important to understand how new therapies for non‐alcoholic steatohepatitis (NASH) may im...

Descripción completa

Detalles Bibliográficos
Autores principales: Connelly, Margery A., Velez Rivera, Jonathan, Guyton, John R., Siddiqui, Mohammad Shadab, Sanyal, Arun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497003/
https://www.ncbi.nlm.nih.gov/pubmed/32638417
http://dx.doi.org/10.1111/apt.15935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497003/
https://www.ncbi.nlm.nih.gov/pubmed/32638417
http://dx.doi.org/10.1111/apt.15935

Ejemplares similares